Black Diamond Therapeutics, Inc.
BDTXNasdaq
$1.79
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↓ -41.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$102.4M
Enterprise Value
-$15.8M
P/E
—
P/S
—
P/B
1.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
$22.3B
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
21382.0%
ROIC
—
Debt / Equity
—
Net Cash
$118.3M
Return 1Y
-44.2%
Company profile
Black Diamond Therapeutics, Inc. discovers, develops, and commercializes medicines for patients with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by non-canonical epidermal growth factor receptor (EGFR) mutations. The company is also developing a brain-penetrant inhibitor of EGFR mutations.
- CEO
- David M. Epstein
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Massachusetts
- Website
- blackdiamondtherapeutics.com
Earnings
BDTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.16↓ -116.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | $0.00 | $70.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$69.6M | -$126.9M | -$92.8M | -$86.5M | -$78.8M | $12.5M |
| Net income | -$67.3M | -$125.6M | -$91.2M | -$82.4M | -$69.7B | $22.4B |
| Diluted EPS | -$2.05 | -$3.47 | -$2.52 | -$1.88 | -$1.27 | $0.39 |
| Operating cash flow | -$52.1M | -$100.1M | -$85.1M | -$66.7M | -$62.3M | $29.6M |
| Free cash flow | -$52.3M | -$102.9M | -$85.3M | -$66.8M | -$62.3M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | 17.9% |
| Net margin | — | — | — | — | — | 31952.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $70.0M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$22.1M | -$18.1M | -$18.3M | $54.5M | -$13.4M | -$11.0M | -$17.6M | -$11.3M |
| Net income | -$19.9M | -$15.6M | -$69.6B | $56.5M | -$10.6M | -$8.5M | $22.3B | -$9.0M |
| Diluted EPS | -$0.36 | -$0.28 | -$0.28 | $0.98 | -$0.19 | -$0.15 | -$0.25 | -$0.16 |
| Operating cash flow | -$14.7M | -$11.3M | -$15.1M | $53.4M | -$9.2M | -$7.8M | -$6.8M | -$10.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | 77.9% | — | — | — | — |
| Net margin | — | — | — | 80.8% | — | — | — | — |
Company news
Jun 6, 2026
May 27, 2026
May 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-19 | Behbahani Ali | Award | 8,961 | $1.66 | $14,875.26 | filing |
| 2026-06-19 | Raman Prakash | Award | 7,907 | $1.66 | $13,125.62 | filing |
| 2026-03-20 | Behbahani Ali | Award | 6,919 | $2.15 | $14,875.85 | filing |
| 2026-03-20 | Raman Prakash | Award | 6,105 | $2.15 | $13,125.75 | filing |
| 2025-12-12 | Behbahani Ali | Award | 5,208 | $2.76 | $14,374.08 | filing |
| 2025-12-12 | Raman Prakash | Award | 4,665 | $2.76 | $12,875.40 | filing |
| 2025-09-19 | Behbahani Ali | Award | 4,291 | $3.35 | $14,374.85 | filing |
| 2025-09-19 | Raman Prakash | Award | 3,843 | $3.35 | $12,874.05 | filing |
| 2025-06-20 | Behbahani Ali | Award | 6,170 | $2.33 | $14,376.10 | filing |
| 2025-06-20 | Raman Prakash | Award | 5,526 | $2.33 | $12,875.58 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.